4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
A clinician-level guide to recognizing, grading, and managing adverse events from PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) across ED, BPH, and pulmonary hypertension indications, with prescribing thresholds, drug interaction tables, and monitoring protocols.
A clinician-facing guide to billing codes, prior-authorization workflows, and payer strategies for PDE5 inhibitors including sildenafil, tadalafil, vardenafil, and avanafil.
Complete drug-drug interaction (DDI) reference for PDE5 inhibitors including sildenafil, tadalafil, vardenafil, and avanafil. CYP3A4 interactions, nitrate contraindications, alpha-blocker timing, and dose adjustments for prescribers.
A board-reviewed, prescriber-level summary of PDE5 inhibitors across special populations including renal impairment, hepatic dysfunction, cardiovascular disease, older adults, and women, with dosing tables and guideline citations.